Objective: To evaluate the effectiveness of pharmacist-led medication review in chronic pain management.
H igh prevalence, associated with long-term morbidity and lack of a permanent cure make chronic pain (CP) one of the most challenging diseases to manage. In the United States, CP affects more than 100 million people and the prevalence is higher than for diabetes, heart diseases, and cancer combined. 1 In Europe, 1 in 5 adults has CP of moderate to severe intensity. 2 Both prescription and nonprescription analgesics are extensively used in CP management but inappropriate and suboptimal use of analgesics has been reported. 3 In 2007, almost 12,000 cases of unintentional drug poisoning involving prescription analgesics 4 were reported and in 2008, almost 15,000 people died from overdoses of opioid analgesics in United States alone. 5 Therefore, the safe and effective use of analgesics is critical to ensure optimum analgesia, to prevent adverse effects, and to minimize abuse of analgesics.
Over the past decade, with the increase in the number of nurse and pharmacist prescribers, interest in the effectiveness of their extended role in the management of different diseases and settings has increased. [6] [7] [8] [9] The limited capacity of general practioners (GPs) and long waiting times for specialist appointments 10 have allowed health care professionals other than GPs to take on key aspects of CP management, with mixed results. 11 A meta-analysis of the effectiveness of pharmacist-led educational interventions for CP management showed a statistically significant reduction in pain intensity and adverse effects, and an improvement in patient satisfaction in those receiving interventions. 11 No benefits were seen in interference from pain on daily life and self-efficacy and reduction in pain intensity was statistically, but not clinically, significant.
As no systematic review has yet evaluated the effectiveness of pharmacist-led medication review for CP management, the aim of this systematic review was to fill this gap. It was prospectively registered with PROSPRO (registration number: CRD42012001957) and the protocol has been previously published. 12 
MATERIALS AND METHODS

Study Selection
The following databases were searched between April and June 2012 using a predefined search strategy. MEDLINE The databases were searched for randomized controlled trials (RCTs) and nonrandomized studies (quasiexperimental, controlled before-and-after study) having at least one control group. Nonrandomized studies were only to be considered for inclusion if fewer than 3 RCTs were eligible for inclusion. Waiting list controls, usual care, attention only, and any other active control were accepted as appropriate controls. Studies were considered for inclusion if one of the intervention arms received pharmacist-led medication review delivered either independently, or as part of a multidisciplinary intervention. Websites of American, Canadian and Royal (British) Pharmaceutical societies were also searched together with the reference lists of the retrieved articles to identify additional eligible studies. Where necessary, the corresponding authors were contacted to obtain additional information and to identify any unpublished studies. The full search strategy is available from the corresponding author on request.
Studies involving CP patients 18 years and above regardless of sex, type and etiology of CP were included. For this systematic review, the definition of International Association for the Study of Pain of CP was used: "Pain without apparent biological value that has persisted beyond the normal tissue healing time (usually taken to be 3 mo)." 13 Studies involving patients with cancer pain were excluded. Only studies published in English (full text or abstract) were considered. Titles and abstracts of the studies were screened independently by 2 authors (M.A.H. and D.P.A.). Full texts of all potentially relevant studies were retrieved. M.A.H. and D.P.A. independently selected studies meeting the predefined inclusion criteria and disagreements were resolved through discussion or a third reviewer (M.B.) was consulted.
Assessment of Risk of Bias and Data Extraction
The risk of bias was assessed using the Cochrane Collaborations' tool by one reviewer (M.A.H.) and verified by another (S.J.C.) using a standardized form. 14 For cluster RCTs, risk of bias was assessed across 2 additional domains including loss of clusters and appropriate statistical analysis. Each domain was assessed and categorized into low risk, high risk, or unclear risk of bias based on the recommendations of Higgins and Green. 14 Disagreements were resolved through discussion and if not resolved, a third reviewer (M.B.) was consulted.
Data were extracted by M.A.H. and verified by M.B. using a standardized data collection form. A third reviewer was consulted (S.J.C.) in cases where disagreements were not resolved through discussion.
Data Synthesis
Review Manager (RevMan 5.1) was used for data analysis. Mean difference was calculated for all continuous variables (eg, pain intensity) when outcomes were measured using the same scale and when different scales were used, standardized mean difference (SMD) was calculated with corresponding 95% confidence intervals (CIs). Relative risk with 95% CIs was calculated for dichotomous variables. The decision to pool data using meta-analysis was based on the clinical homogeneity in terms of the population, intervention, outcome measures, and timing of outcome measures of all the included studies. Clinical homogeneity was determined by discussion among the review authors and clinically heterogenous trials were not combined statistically. Statistical heterogeneity was determined by using w 2 and I 2 statistic. Statistical heterogeneity determined the choice of using a random-effects or fixed-effects model for meta-analysis. A w 2 P-value >0.1 and an I 2 value <50% was used to indicate statistical homogeneity. 14 A randomeffects model was used to combine clinically homogenous but statistically heterogenous clinical trials, whereas clinical and statistical homogenous trials were combined using the fixed-effects model.
As the trials measured the same outcomes using different scales, data were pooled using SMD for each outcome. To interpret SMD, it was reexpressed in the units of a specific measurement scale for 2 of the 3 outcome measures that were statistically combined, pain intensity and physical functioning. 14 For the third outcome measure, patient satisfaction, SMD was reexpressed using rules of thumbs for effect sizes. 14 Only the summary measure of effect was back-transformed to enhance clinical interpretation. If the "adjusted" change in score derived from regression model accounting for baseline measurements was reported, it was preferred over the crude change in score to calculate SMD. 14 Meta-analysis was undertaken for 3-and 6-month follow-ups. Figure 1 illustrates the search process and the reasons for exclusion. Nine reports of 5 studies met the inclusion criteria for review. [15] [16] [17] [18] [19] [20] [21] [22] [23] Two trials were conducted in the United Kingdom 19-21 and 1 each in Canada, 22 Germany, 18 and the United States. 23 The included studies comprised 3 individually randomized 19,21,23 and 2 cluster-randomized controlled studies 18, 22 randomizing 1035 patients in total. All followed up the patients for at least 3 months, 3 for 6 months and 1 for 12 months. All had their first follow-up at 3 months except for Hoffman et al 18 where follow-up was at 4 months. In total, 131 patients (12.7%) were lost to the first follow-up. Two trials included patients with CP of mixed etiologies, 21,23 2 involved patients with osteoarthritic knee pain 19, 22 and 1 involved chronic headache and migraine patients. 18 In 4 trials where sex was reported, the majority of the participants were women (61.8%). 18, 19, 22, 23 The mean age of participants varied between 42.70 years (SD ± 13) 18 and 67.9 years (SD ± 8.2). 19 One study 16, 21 did not report age and participants in the Gammaitoni et al 23 study ranged from 35 to 64 years.
RESULTS
Characteristics of Studies
Nature and Delivery of Intervention
In 3 trials 18,19,21 the intervention was pharmacist-led medication review alone while in the other 2 22,23 the intervention involved medication review as part of a multicomponent intervention ( Table 1 ). Marra et al 22 used a face-to-face consultation with a pharmacist who educated patients on aspects of osteoarthritis, conducted medication review, referred patients to a physiotherapist-guided exercise program, and requested patients' primary care physicians to approve their inclusion in the exercise program. Over the 6-month follow-up period, 297 patient-pharmacist consultations generated 255 comments and recommendations, including 49 medication-related recommendations to patients' primary care physicians. The control group received an educational leaflet on knee osteoarthritis developed by the Canadian Arthritis Society.
In the Gammaitoni et al trial, 23 the intervention had 2 components consisting of a specialized prescription service provided by a palliative care pharmacy company (PainRxperts) that delivered patients' medication and proactive monitoring of patients' medication for any potential or actual drug-related problem by a palliative care trained pharmacist. In total, 81 phone calls were made by the pharmacist including 45 to patients (mean 1.2 calls per patient) and 36 to the clinic staff. On an average, each patient contact lasted 12 minutes, and 9 minutes for clinic staff. Fifteen out of 16 recommendations made to the clinic staff were accepted. The control group received usual care as before study.
Hay et al 19 used 2 independent intervention groups: pharmacy review and community physiotherapy. Only data for the pharmacy review group were extracted for this systematic review. Participants in the pharmacy review group received an enhanced pharmacy review plus an education leaflet from an experienced community pharmacist in general practice surgeries. The trial protocol permitted 3 to 6 sessions of approximately 20 minutes each over 10 weeks. In total, 335 pharmacist-patient consultations took place (mean 3.2 per patient; range, 2 to 5). The mean time spent per patient was around 63 minutes in 3 sessions. Control participants received the same education leaflet and a telephone call from a rheumatology nurse to reinforce the leaflet advice within 7 days of randomization.
Hoffmann et al's 18 intervention group received an individualized counseling session by trained community pharmacists, optimizing pharmacotherapy, promoting selfmanagement, goal setting, and pacing activities. Each patient received approximately 2 hours of counseling and each pharmacy counseled 4.6 ± 3.06 patients on an average (range, 1 to 15). Control participants continued to receive usual pharmaceutical consultations with pharmacists not formally trained in headache/pain management.
Bruhn and colleagues 16,20,21 used 2 independent intervention groups: pharmacist medication review either with recommendations to the GP or pharmacist prescribing. Data on the nature and duration of the intervention were not available. Authors were unable to provide data due to funding restrictions.
Risk of Bias
Three trials 19,22,23 described adequate methods for randomization ( Fig. 2) , including a random number generator, 19 statistician generated values from a uniform (0, 1) distribution, 22 and a computer program used to randomly assign names to either the intervention or control group. 23 Only Hay et al 19 described an adequate method of allocation concealment (sequentially numbered opaque envelops). Allocation concealment was not possible for the clusterrandomized trials 18, 22 and is not considered an issue. 14 In all the trials, the nature of interventions made it impossible to blind pharmacists delivering and the participants receiving them. Outcome assessors were blinded in 2 trials only. 19, 22 Hoffmann et al 18 collected data through a computer-aided, standardized telephone interview, but it was not made clear whether people who handled and analyzed the data were blinded or not. All trials 18, 19, 21, 22 except one 23 used the intention to treat principle, minimizing attrition bias.
Only 1 trial 22 showed significant differences between intervention and control at baseline in pain scores measured by the Health Utilities Index-3 (HUI-3), 24 
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Not an RCT/CCT = 14 Could not retrieve full text=3 Not in English= 1 instrument to measure quality of life (QoL), between intervention and usual care groups. However, no significant differences in pain scores occurred when measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. 25 Participants in the intervention group were slightly more educated (86% vs. 79% with high school education), belonged to higher socioeconomic class (71% vs. 59% with an income over $50,000), and were of Asian origin (21% vs. 9%) compared with controls. Only 1 patient was lost to follow up in each group in the Marra et al 22 study and the authors took "clustering" into consideration in sample size calculation and data analysis. However, in the Hoffmann et al 18 clusterrandomized trial, the authors did not use appropriate statistical techniques and did not allow for the clustering effect in sample size calculation and data analysis.
Outcomes Assessment Pain Intensity
Pain intensity was reported in all the trials using different scales. Gammaitoni et al 23 measured pain intensity, according to the Health Background Questionnaire-Initial Patient Visit, on a 0 to 10 numerical rating scale (NRS), where 0 = no pain and 10 = pain as bad as you can imagine. 26 Hay et al 19 reported pain intensity with the NRS and on a 0 to 20 subscale of WOMAC. 25 Bruhn et al 21 assessed pain intensity using the pain intensity subscale of the Chronic Pain Grade questionnaire, a 7-item questionnaire to measure pain intensity, severity, and functional disability. 27 Marra et al 22 Four studies showed a significant reduction in pain scores at follow-up. [18] [19] [20] [21] [22] Although, Hay et al 19 reported a statistically significant reduction in pain scores at 3-month follow up (P = 0.04), they were not significant at 6 (P = 0.3) and 12 months (P = 0.5). Hoffmann et al 18 reported a significant reduction in "untreated" pain intensity in both intervention (P < 0.001) and control group (P < 0.001); however, reduction in "treated" pain intensity remained nonsignificant in both intervention wThe second intervention group also received medication review as part of intervention. Data for only 1 intervention group is presented here. C indicates control group; C-RCT, cluster-randomized controlled trial; GP, general practitioner; I, intervention group; I-RCT, individual randomized controlled trial; MR, medication review.
(P = 0.52) and control groups (P = 0.92) at 4-month follow-up.
Pain scores were pooled using meta-analysis. The study by Hoffmann et al 18 involved patients with chronic headache and migraine so was clinically heterogenous and not combined statistically. The data reported by Bruhn et al 21 were insufficient for meta-analysis.
Compared with the control group, at 3 months there was a significant reduction in pain intensity in the intervention group with SMD of -0.37 (95% CI, À 0.58 to À0.16; Fig. 3 ). This corresponds to a 0.83-point reduction on an 11-point NRS (95% CI, À1.28 to À 0.36). There was no heterogeneity in the result (I 2 = 0%). Only 2 studies reported pain intensity at 6 months. 19, 22 Meta-analysis showed a significant reduction in pain intensity in the intervention group compared with the control (SMD -0.31 [95% CI, À 0.53 to À 0.09]) corresponding to a 0.7-point reduction on a 0 to 10 NRS (95% CI, À1.19 to À0.20). There was a slight heterogeneity in the result (I 2 = 39%; w 2 = 1.64, df = 1, P = 0.20) that was considered statistically nonsignificant. 14 
Physical Functioning
Physical function was an outcome in all the studies. It was assessed using a 0 to 10 22 and 0 to 68 physical functioning subscale of WOMAC 19 and the physical health subscale of SF-36 18 and SF-12, 16 valid instruments to measure QoL. 28, 29 Pain interference was assessed with various daily activities (general activity, mood, waking, normal work, relationships, sleep, and enjoyment of life) as part of Pharmacotherapeutic Pain Inventory, 23 a survey instrument derived from the BPI 30 and the Health Background Questionnaire-Initial Patient Visit. 26 Instead of reporting a recommended summary score from these 7 interference items, 30 the authors reported items individually.
Only Marra et al 22 reported a statistically significant improvement in physical functioning at 3 months (À0.65; 95% CI, À 1.20 to À 0.10) and 6 months (À 0.84; 95% CI, À1.45 to À 0.24) in the intervention group compared with the control.
Data were pooled using meta-analysis for 3 studies excluding one for clinical heterogeneity 18 and one for insufficient data. 16 Study or Subgroup
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Hay statistically significant improvement in the intervention group with SMD of À0.38 (95% CI, À0.58 to À0.18) compared with the control group (Fig. 4) . This effect is equivalent to 4.84 points (95% CI, À7.38 to À 2.29) on a 0to 68-point function subscale of WOMAC. 26 There was no heterogeneity in the result (I 2 = 0%). Two trials reported physical functioning status at 6 months. 19, 22 Meta-analysis showed a significant improvement in the physical functioning at 6 months follow-up and in the intervention group compared with the control group with SMD À 0.30 (95% CI, À0.51 to À 0.09) corresponding to À3.82 points (95% CI, À 6.49 to À 1.14) on WOMAC 0 to 68 function subscale. 26 There was nonsignificant heterogeneity in the result (I 2 = 33%).
Patient Satisfaction
Three studies reported patient satisfaction as an outcome. 16, 19, 23 This was assessed using: a modified version of the Treatment Helpfulness Questionnaire, 23 a validated measure to assess patient satisfaction with chronic pain service 31 ; as a dichotomous outcome (satisfied, not satisfied) 19 ; and using Likert scale ratings of statements about pain and pharmacist consultations, with open-ended questions about pharmacist consultations. 20 Gammaitoni et al 23 only compared the difference in patient satisfaction from baseline to 3-month follow-up for intervention and control groups independently, but did not compare control with the intervention group. Compared with the baseline, in the intervention group, patients were significantly more satisfied with various components of the pharmaceutical care program including pharmacy service, delivery of medication, pharmacist phone calls, time spent in obtaining medications), pharmacist medication counseling, and information provided by the pharmacist. However, there was no significant difference in satisfaction with the whole program domain (P = 0.72) of the patient satisfaction survey. In the Hay et al study, 19 intervention group patients were significantly more satisfied with treatment at 3 and 12 months follow-up but not at 6 months. Bond et al 20 linked to Bruhn et al 16, 21 reported that 85% (38/46) of the patients in the prescribing arm were totally satisfied with the received treatment. Patient satisfaction rates were not reported for the other intervention arm (medication review alone) and control group.
Data for patient satisfaction were pooled for 2 studies (Fig. 5 ). 19, 23 Meta-analysis showed significantly greater patient satisfaction in the intervention group with SMD À0.39 (95% CI, À0.68 to À0.10). Using the universal rule of thumb, this effect size corresponds to "small to moderate effect." 14, 32 QoL Three studies assessed QoL 16, 18, 22 using the Medical Outcomes General Health Survey (SF-36), 18 a 36-item generic tool 29 ; the SF-12, 21 and the WOMAC (global) and HUI-3, a generic and preference-scored instrument for measuring health status and health-related QoL. 24 
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DISCUSSION
Main Results
The search strategy identified 5 studies that met the inclusion criteria. Pharmacists delivered interventions in different settings such as community pharmacies, 18, 22 general practices, 19, 21 and university pain clinic 23 indicating that the intervention can be potentially delivered in multiple settings. Furthermore, the included trials involved patients with various CP etiologies, demonstrating that the pharmacist-led medication review may be effective for all different types of CP conditions. Trials originated from the United Kingdom, 19, 21 the United States, 23 Canada, 22 and Germany 18 indicated a growing interest in evaluating the role of pharmacists in CP management in the developed world. This may be due to the growing necessity to involve health care professionals such as pharmacists and nurses actively in direct patient care to reduce the workload on GPs and other primary care physicians in these countries.
The risk of bias was low or unclear across all the domains, except for blinding of participants and personnel where there was high risk of bias across all trials. The nature of the intervention, made it impossible to blind the pharmacists conducting medication reviews and the patients receiving it as, in most instances, the medication review was conducted face-to-face. Outcome assessors were blinded in 2 of 3 trials used in the meta-analysis, and in the third trial the outcome assessments were carried out using a standardized computer-aided interview, minimizing detection bias. Clinical homogeneity was considered before pooling data statistically. Data from a study by Hoffmann et al 18 were not considered for meta-analysis as the study involved patients with chronic headache and migraine, which is a neurological condition and has an episodic nature 33 unlike other CP conditions and requires different treatment. The full report of Bruhn et al 21 was not published at the time this review was conducted and the data reported in conference abstracts 16, 20, 21 were insufficient to be pooled statistically. The corresponding author was unable to provide additional data due to restrictions by the funding agency. Other trials were relatively similar in terms of nature of intervention, patient follow-up, and patients' pain scores. Meta-analysis was conducted at 2 time points; 3 and 6 months to limit any bias arising from combining short-term trials with long-term trials. 34 Meta-analysis showed a statistically significant reduction in pain intensity and significant improvement in physical functioning in the intervention group compared with controls. However, the clinical significance of these findings is arguable and needs careful consideration. The use of average results of continuous data (eg, pain intensity) can be misleading 35 as the population distributions of pain scores and pain relief are usually "U-shaped" (rather than normally distributed), therefore patients tend to have either very good or very poor pain relief. Pain scores and pain relief should therefore be reported as percentage of patients responding to the treatment instead of average pain scores, to reflect the actual number who improved or deteriorated. All the trials included in the systematic review reported mean pain score rather than reporting percentages of patients responding to the treatment. Furthermore, medication review was conducted as part of multicomponent interventions in 3 of the 5 studies so the "active ingredient" of the intervention is not known. However, the impact of the intervention on other drug-related outcomes such as reduction in side effects, 17 in a report linked to Hay et al, 19 the reduction in the use of Non Steroidal Anti Inflammatory Drugs 19 ; and the high acceptance of pharmacists' recommendations suggest that pharmacist-led medication review is an important component in overall pain management and can improve patient-reported outcomes. 18, 22, 23 
Implications for Pharmacy Practice and Policy
The findings of this systematic review have raised 2 questions that need to be considered by service commissioners and policy makers before a wider role for pharmacists in chronic pain management is put into practice. Firstly, certain issues related to delivery of the intervention such as "how much," "how often," and "how long," must be carefully considered as limited exposure to the service may not be adequate to achieve desired outcomes and prolonged use of the service may not be cost-effective and may put an additional burden on health care systems. Furthermore, it is still unknown whether the pharmacist-led medication review benefits all types of chronic pain patients or only certain ones. However, medication review by an expert pharmacist may reduce drug-related problems and adverse effects in all patients irrespective of the pain etiology. Secondly, short courses, programs, and residency training are needed to provide specialized education and training in pain management to pharmacists to achieve maximum clinical benefit, as advocated in the past. 36 To date, such training programs are not widely available, especially outside the United States. 37,38 Training programs to produce pharmacists skilled in pain management are essential to ensure the sustainability and clinical effectiveness of pharmacist-led pain management service.
Implications for Future Research
The current evidence suggests that pharmacist-led medication review is effective in reducing pain intensity, medication-related adverse effects, and improving physical functioning. Future research should evaluate the optimum and most cost-effective mode, method, and duration of delivery of the intervention to achieve maximum clinical benefit. Improved quality of reporting of clinical trials involving chronic pain patients is needed. In addition to CONSORT guidance on the conduct and reporting of clinical trials, 39 the researchers should also adhere to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidance in designing, conducting, and reporting their findings. 34, [40] [41] [42] Trials involving only non cancer pain patients were included and it would be interesting to evaluate the effectiveness of pharmacist-led medication review among patients with cancer pain, as effective management of cancer pain is very important in overall cancer management, especially in end of life care.
Limitations
In terms of the design of the systematic review there were 2 major limitations. Firstly, only studies reported in English were included, which may have led to language bias. 43 One study, 44 published in Spanish, was excluded during screening of full texts. However, conflicting results have been reported in the literature examining the extent of the effect of language bias on the findings of systematic reviews. 45, 46 Secondly, publication bias may have been introduced as no attempt was made to locate unpublished trials (gray literature). The findings of the research evaluating the impact of inclusion or exclusion of "gray" literature in meta-analysis of RCTs are inconsistent. 47, 48 Systematic review authors in future may consider including studies not published in English and unpublished studies, to overcome the above-mentioned limitations.
CONCLUSIONS
Pharmacists can play an important role in improving CP management. They can deliver interventions independently and as part of multidisciplinary teams in both community and hospital settings. The present systematic review suggests that pharmacist-led medication review is effective in reducing pain intensity and improving physical functioning and patients were generally satisfied with the service provided by the pharmacists. There is also weak evidence of preventing and stopping adverse effects associated with the use of medicines among CP patients. The clinical significance of these findings remain to be established. Future clinical trials evaluating the effectiveness of pharmacist-led interventions in CP must adhere to IMMPACT guidance [40] [41] [42] in designing, conducting, and reporting theirs findings in addition to CONSORT guidance. 39 As the focus of care shifts from hospital to community, pharmacists especially community pharmacists have the potential to reduce the CP burden on health care system and society by ensuring the safe and effective use of medicines.
